Pradaxa, Eliquis antidotes post impressive new study data; Never mind taxes, Mylan wants U.S. to protect it from Teva;

@FiercePharma: ICYMI Friday: Biosimilar of Novartis' eye drug Lucentis launched in India. Report | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. FiercePharmaManufacturing feature | Follow @EricPFierce

@CarlyHFierce: ICYMI: Teva turns up the heat on Mylan, taking its stake past critical threshold. Article | Follow @CarlyHFierce

Breakthrough anti-anticoagulants designed to counter the effects of Boehringer Ingelheim's Pradaxa, and Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) Eliquis, unveiled stellar Phase III data Monday. Report

Mylan ($MYL) may have moved its headquarters overseas to win a tax break, but it still wants to be treated as a U.S. company--at least when it comes to fending off a takeover by Teva ($TEVA). Report

GlaxoSmithKline ($GSK) unloaded two of its meningitis vaccines--Nimenrix and Mencevax--to Pfizer ($PFE) to satisfy antitrust worries after its buyout of Novartis' ($NVS) vaccines business. Report

Eisai won a new FDA approval for its seizure drug Fycompa, in patients with primary generalized tonic-clonic (PGTC) seizures. Release

A senior Merck ($MRK) scientist faces drug charges after receiving a home delivery of a chemical commonly used to make the club drug GHB, NJ.com reports. Story

Medical Device News

@FierceMedDev: ICYMI from FierceDrugDelivery: Teva partners with Microchips Biotech to deliver drugs via wirelessly controlled implant. Article | Follow @FierceMedDev

@VarunSaxena2: FDA approves novel tongue sensor for the blind. ICYMI Friday | Follow @VarunSaxena2

**@EmilyWFierce:**Loaded up with debt from M&A binge, Valeant still needs more deals. More from FiercePharma | Follow @EmilyWFierce

Foundation Medicine teams up with IMS Health for cancer precision medicine project. More

Report: TAVR procedures seen to change cardiac care in the U.S. Story

Biotech News

@FierceBiotech: FierceBiotech Radio on GlaxoSmithKline rumors, Allergan's new identity and Axovant's IPO. Listen | Follow @FierceBiotech

@JohnCFierce: Anthem going after Cigna -- payer consolidation will increase pressure on U.S. drug pricing. NYT story | Follow @JohnCFierce

@DamianFierce: True Detective is terrible and I'm going to watch the whole season. I don't deserve to vote. | Follow @DamianFierce

Breakthrough anti-anticoagulants from Boehringer, Portola post stellar PhIII data. Report

Kite and bluebird join forces with some cutting-edge cancer tech. Story

Biotech billionaire Soon-Shiong steers immuno-oncology player Conkwest to $172.5M IPO. Article

Animal Health News

Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit. News

Startup Rex clears $1M, starts hiring in KC Animal Health Corridor. More

Zoetis to cut 165 workers from NJ headquarters as downsizing gets underway. Story

Report: DNA-based injections to fuel growth of animal vaccines market. Item

Vets and pharma execs gather in DC to trade notes on pets in cancer research. Article

Biotech IT News

Pfizer's Lipset plots path to mainstream acceptance of experimental trial techs. News

DIA starts with a flurry of hires, deals and product updates. Report

GSK gives Altius $95M and a mission to hire computer scientists for 'living genome' research. More

REMS website overhauled by FDA to simplify access to information. Story

FDA digs into PatientsLikeMe's data to add patients' voices to safety monitoring. Article

Pharma Marketing News

Social listening should be a no-brainer for pharma, study finds. Report

It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA. Item

AstraZeneca nabs top pharma ad award at Cannes amid slim product-specific field. Article

Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More

Pharma ad budgets to dip in 2016, but J&J, Pfizer, Roche and Novartis should still top $2B. Story

And Finally... New scripts for Gilead Sciences's ($GILD) hep C drug Harvoni have started to decelerate, analysts say. Report